0.7373 USD
+0.02 (+2.4%)
0.73 USD
-0.01 (-0.99%)
We assign a fundamental rating of 3 out of 10 to KAPA. KAPA was compared to 529 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KAPA as it has an excellent financial health rating, but there are worries on the profitability. KAPA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year KAPA has reported negative net income.
KAPA had a negative operating cash flow in the past year.
1.2 Ratios
With a Return On Assets value of -62.76%, KAPA perfoms like the industry average, outperforming 40.64% of the companies in the same industry.
Looking at the Return On Equity, with a value of -66.05%, KAPA is in line with its industry, outperforming 57.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.76% | ||
| ROE | -66.05% | ||
| ROIC | N/A |
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KAPA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KAPA has more shares outstanding than it did 1 year ago.
KAPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 18.83 indicates that KAPA is not in any danger for bankruptcy at the moment.
KAPA has a Altman-Z score of 18.83. This is amongst the best in the industry. KAPA outperforms 88.28% of its industry peers.
There is no outstanding debt for KAPA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 18.83 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 16.56 indicates that KAPA has no problem at all paying its short term obligations.
KAPA has a Current ratio of 16.56. This is amongst the best in the industry. KAPA outperforms 93.01% of its industry peers.
A Quick Ratio of 16.56 indicates that KAPA has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 16.56, KAPA belongs to the best of the industry, outperforming 93.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.56 | ||
| Quick Ratio | 16.56 |
3. Growth
3.1 Past
The earnings per share for KAPA have decreased strongly by -33.55% in the last year.
EPS 1Y (TTM)-33.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -13.70% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-30%
EPS Next 2Y-28.45%
EPS Next 3Y-33.89%
EPS Next 5Y-13.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KAPA. In the last year negative earnings were reported.
Also next year KAPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
KAPA's earnings are expected to decrease with -33.89% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.45%
EPS Next 3Y-33.89%
5. Dividend
5.1 Amount
No dividends for KAPA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.7373
+0.02 (+2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.11%
Inst Owner Change105.14%
Ins Owners32.72%
Ins Owner Change0%
Market Cap15.35M
Revenue(TTM)N/A
Net Income(TTM)-5.06M
Analysts82.22
Price Target8.5 (1052.86%)
Short Float %0.98%
Short Ratio0.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.77%
Min EPS beat(2)-42.6%
Max EPS beat(2)-2.94%
EPS beat(4)0
Avg EPS beat(4)-56.62%
Min EPS beat(4)-124.09%
Max EPS beat(4)-2.94%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4.76%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)-8.33%
EPS NY rev (3m)-8.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2 | ||
| P/tB | 2.03 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.37
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.76% | ||
| ROE | -66.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 16.56 | ||
| Quick Ratio | 16.56 | ||
| Altman-Z | 18.83 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y-30%
EPS Next 2Y-28.45%
EPS Next 3Y-33.89%
EPS Next 5Y-13.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-175.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-677.2%
EBIT Next 3Y-180.07%
EBIT Next 5Y-129.35%
FCF growth 1Y-4982.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4982.72%
OCF growth 3YN/A
OCF growth 5YN/A
KAIROS PHARMA LTD / KAPA FAQ
What is the ChartMill fundamental rating of KAIROS PHARMA LTD (KAPA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to KAPA.
What is the valuation status for KAPA stock?
ChartMill assigns a valuation rating of 0 / 10 to KAIROS PHARMA LTD (KAPA). This can be considered as Overvalued.
How profitable is KAIROS PHARMA LTD (KAPA) stock?
KAIROS PHARMA LTD (KAPA) has a profitability rating of 1 / 10.
What is the expected EPS growth for KAIROS PHARMA LTD (KAPA) stock?
The Earnings per Share (EPS) of KAIROS PHARMA LTD (KAPA) is expected to decline by -30% in the next year.